ClinicalTrials.gg
CompletedNCT02431312Updated Oct 15, 2019

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

A Phase 1 interventional study of INO-1800 and INO-9112 in Hepatitis B, sponsored by Inovio Pharmaceuticals. Completed at 22 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Inovio Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 197 studies in Hepatitis B with a site in United States — 15 open to participants now, 27 under way, 3 of them phase 3. Hepatitis B · United States.

Enrollment
74th of 148
90 · median 90
Started
2015
with 5 others
Phase 1
29 of 197
2 open now
Registered
118th of 197
by date

Among the 197 studies in Hepatitis B with a site in United States, this one is the 74th largest by enrollment of the 148 interventional ones that give a count, is one of 6 that started in 2015, is one of 29 in phase 1, and was the 118th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

15 of the 197 studies in Hepatitis B with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Hepatitis B with a site in United States, or all of them as a file.
02

Study summary

This was an open-label study that evaluated the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen [HBsAg] and Hepatitis B core antigen [HBcAg]) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide analogue treated participants.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Chronic HBV
  • immunotherapy
  • DNA vaccine
  • electroporation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic virus infection
  • Negative for Hepatitis A IgM, C, D and
  • Liver , Fibroscan® or equivalent elastography-based test obtained within the past 6 months demonstrating liver disease without evidence of bridging fibrosis or cirrhosis supported by count greater than the central laboratory LLN at screening
  • Positive for Hepatitis B surface antigen (≥250 IU/mL at screening)
  • Nucleos(t)ide treatment for at least 1 year with ongoing nucleos(t)ide analogue treatment at randomization
  • HBV DNA \<90 IU/mL for ≥6 months prior to randomization
  • Screening laboratory values within normal range
  • ≤1.5x (ULN) from 2 measurements separated by at least 14 days during the 6 months prior to randomization and ALT at screening ≤1.5x ULN
  • AST, TBili, DBili, GGT, Alk Phos and albumin within normal range or judged to be not by PI and medical monitor at screening
  • For men and women who are not [i.e. ≥ 12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone replacement] or surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females) agreement to remain abstinent or use 1 highly effective or combined methods that result in a failure rate of \< 1% per year during the treatment period and at least through week 12 after last dose

Exclusion criteria

EXCLUSION CRITERIA:

  • Pregnant or breastfeeding females
  • Positive serum pregnancy test at screening or positive urine pregnancy test at randomization
  • Use of topical at or near the intended administration site
  • disorders, transplant recipients, other including any concurrent condition requiring the use of immunosuppressive/immunomodulating agents (eye drop-containing and infrequent inhaled corticosteroids are permissible)
  • Need for systemic antiviral treatment (other than for chronic infection)
  • Documented history or other evidence of decompensated liver disease (e.g., ascites, bleeding from esophageal varices, clinical classification B or C)
  • History of liver cirrhosis demonstrated by , Fibroscan® or equivalent elastography-based test
  • History of other evidence of a medical condition associated with chronic liver disease [e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), toxin exposure, thalassemia, etc.]
  • Documented history or other evidence of metabolic liver disease within 1yr of randomization
  • Abnormal renal function including serum creatinine > or calculated \<70 mL/min (using the Cockcroft Gault formula)
  • History of or suspicion of HCC
  • Screening alpha fetoprotein ≥13 ng/mL
  • Prior history or current other than adequately treated BCC, unless history of BCC is near intended administration site
  • History of significant medical conditions [e.g., cardiac (including ventricular or supraventricular arrhythmias), renal disease, pulmonary, gastrointestinal, neurological]
  • Significant acute infection (e.g., influenza, local infection) or any other illness within 2 weeks of randomization
  • Administration of any blood product within 3 mon of randomization
  • History of seizures (unless seizure free for 5yrs)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Group A: low dose, standard regimen

    Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.

    Biological: INO-1800 · Drug: Nucleos(t)ide Analogue Treatment

  • Experimental
    Group A: mid dose, standard regimen

    Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.

    Biological: INO-1800 · Drug: Nucleos(t)ide Analogue Treatment

  • Experimental
    Group A: high dose, standard regimen

    Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.

    Biological: INO-1800 · Drug: Nucleos(t)ide Analogue Treatment

  • Experimental
    Group B: mid dose, standard regimen

    Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.

    Biological: INO-1800 · Biological: INO-9112 · Drug: Nucleos(t)ide Analogue Treatment

  • Experimental
    Group B: high dose, standard regimen

    Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.

    Biological: INO-1800 · Biological: INO-9112 · Drug: Nucleos(t)ide Analogue Treatment

  • Active comparator
    Active Control: nucleos(t)ide analogue treatment

    Participants continued treatment with nucleos(t)ide analogue treatment.

    Drug: Nucleos(t)ide Analogue Treatment

Interventions

  • BiologicalINO-1800

    INO-1800 delivered by EP

  • BiologicalINO-9112

    INO-9112 delivered by EP

  • DrugNucleos(t)ide Analogue Treatment

    Continued treatment with nucleos(t)ide analogue

06

What researchers measure

Primary outcomes

  1. Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs)

    Composite outcome measure consisting of multiple measures, including: 1. Local pain immediately after Study Treatment/EP and at select times using a visual analog scale (VAS) from 0 to 10, with 0 representing "No Pain" and 10 representing "Worst Pain" 2. Frequency and severity of local and systemic events for at least 7 days after Study Treatment/EP 3. Frequency and severity of laboratory abnormalities 4. Frequency and severity of all adverse events 5. Changes in vital signs

    Time frame: Signing of ICF through up to 76 weeks following the first dose

Secondary outcomes

  1. Immunogenicity Assessment

    Composite outcome measure consisting of multiple measures, including 1. Breadth and Magnitude of antigen specific cellular immune responses * Interferon-ɣ ELISpot * Flow Cytometry for T-cell activation, cytolytic phenotype, memory phenotype 2. Breadth and Magnitude of antigen specific ELISA

    Time frame: Baseline (screening and first dose) and select points up to 76 weeks after the first dose

  2. Viral/Antiviral Assessment

    Composite outcome measure consisting of multiple measures, including: 1. Evaluate effect on HBsAg kinetics as measured in the quantitative HBsAg assay 2. Evaluate effect on maintenance of HBV DNA suppression (\< 90 IU/ml) as measured in the quantitative viral load assay

    Time frame: Screening and/or first dose and select points up to 76 weeks after the first dose

Other outcomes

  1. Exploratory Assessment

    Composite outcome measure consisting of multiple measures, including: 1. Relationship between immunogenicity and antiviral response 2. Expression of individual markers potentially predictive of immunogenic and antiviral responses

    Time frame: Screening and/or first dose and select points up to 76 weeks after the first dose

07

Study locations

22 sites
  • Research and Education, Inc.
    San Diego, California 92105, United States
  • University of Miami Schiff Center for Liver Disease
    Miami, Florida 33136, United States
  • Northwell Health
    Manhasset, New York 11030, United States
  • Mount Sinai - PRIME
    New York, New York 10029, United States
  • UC Physicians Company, LLC/Division of Digestive Diseases
    Cincinnati, Ohio 45267, United States
  • Philadelphia VA Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Harbourview Medical Center
    Seattle, Washington 98104, United States
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The University of Hong Kong
    Hong Kong, 00000, Hong Kong
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • The Medical City
    Pasig City, 1605, Philippines
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • Chang Gung Memorial Hospital
    Linkou, Taoyuan County 333, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Siriraj Hospital, Mahidol University
    Bangkoknoi, Bangkok 10700, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Tha Muang, Chiang Mai 50200, Thailand
  • Srinagarind Hospital
    Khon Kaen, Muang District 40002, Thailand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in May 2018, 40 months.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 40 months is above that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2015
First posted
May 1, 2015
StartActual
Jan 12, 2015
Primary completionActual
May 22, 2018
CompletionActual
May 22, 2018
Last update
Oct 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02431312
Responsible party
Sponsor
First posted
May 1, 2015
Start date
Jan 12, 2015
Primary completion
May 22, 2018
Completion
May 22, 2018
Last update
Oct 15, 2019

Study contacts

ShuPing Yang, MD, PhD
study director · Inovio Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocakinogene sifuplasmid

Start the discussion